JP2013508289A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508289A5
JP2013508289A5 JP2012534359A JP2012534359A JP2013508289A5 JP 2013508289 A5 JP2013508289 A5 JP 2013508289A5 JP 2012534359 A JP2012534359 A JP 2012534359A JP 2012534359 A JP2012534359 A JP 2012534359A JP 2013508289 A5 JP2013508289 A5 JP 2013508289A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nitrite
composition according
plasma concentration
maintained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012534359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508289A (ja
JP5758904B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052683 external-priority patent/WO2011047161A1/en
Publication of JP2013508289A publication Critical patent/JP2013508289A/ja
Publication of JP2013508289A5 publication Critical patent/JP2013508289A5/ja
Application granted granted Critical
Publication of JP5758904B2 publication Critical patent/JP5758904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012534359A 2009-10-14 2010-10-14 ニトライトの医薬製剤及びそれらの使用 Expired - Fee Related JP5758904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25148309P 2009-10-14 2009-10-14
US61/251,483 2009-10-14
PCT/US2010/052683 WO2011047161A1 (en) 2009-10-14 2010-10-14 Pharmaceutical formulations of nitrite and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015113882A Division JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2013508289A JP2013508289A (ja) 2013-03-07
JP2013508289A5 true JP2013508289A5 (enExample) 2013-10-31
JP5758904B2 JP5758904B2 (ja) 2015-08-05

Family

ID=43855036

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012534359A Expired - Fee Related JP5758904B2 (ja) 2009-10-14 2010-10-14 ニトライトの医薬製剤及びそれらの使用
JP2015113882A Expired - Fee Related JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用
JP2017074888A Pending JP2017141275A (ja) 2009-10-14 2017-04-05 ニトライトの医薬製剤及びそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015113882A Expired - Fee Related JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用
JP2017074888A Pending JP2017141275A (ja) 2009-10-14 2017-04-05 ニトライトの医薬製剤及びそれらの使用

Country Status (10)

Country Link
US (4) US10463689B2 (enExample)
EP (1) EP2488035B1 (enExample)
JP (3) JP5758904B2 (enExample)
CN (2) CN102686111A (enExample)
AU (1) AU2010306755B2 (enExample)
CA (1) CA2777066C (enExample)
ES (1) ES2633618T3 (enExample)
IL (1) IL219155A0 (enExample)
IN (1) IN2012DN03428A (enExample)
WO (1) WO2011047161A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649334B2 (en) 2007-11-15 2017-05-16 The Uab Research Foundation Use of nitrite salts in chronic ischemia
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
CA2777066C (en) 2009-10-14 2020-02-18 TheraVasc, LLC Pharmaceutical formulations of nitrite and uses thereof
MX354702B (es) 2011-08-17 2018-03-16 Univ Texas Metodo de produccion de niveles fisiologicos y terapeuticos de oxido nitrico por medio de un sistema de suministro oral.
US8627204B2 (en) * 2011-10-18 2014-01-07 Microsoft Corporation Custom optimization of web pages
CN105358160A (zh) * 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途
WO2014183108A1 (en) * 2013-05-10 2014-11-13 Nitromega Corp. Nutritional or dietary supplements containing fatty acids and nitrite
GB201309092D0 (en) 2013-05-20 2013-07-03 Edixomed Ltd Transdermal delivery system
EP3463296A4 (en) 2016-06-06 2020-02-19 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Pharmaceutical formulations of nitrite uses thereof
CA3052206A1 (en) 2017-02-20 2018-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
US11850271B1 (en) * 2023-05-16 2023-12-26 King Faisal University Topical skin cream
WO2026006722A1 (en) 2024-06-28 2026-01-02 The Regents Of The University Of Michigan Nitric oxide generating medical devices and methods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) * 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) * 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
DE59905248D1 (de) 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1492509A1 (en) 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
EP1495026A4 (en) * 2002-03-20 2008-07-09 Univ Queensland METHOD AND COMPOSITIONS CONTAINING STAIN OXIDE DISPENSERS AND OPIOLD ANALGETICS
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
EP1653978B1 (en) 2003-07-09 2020-06-03 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of nitrite salts for the treatment of cardiovascular conditions
CA2536173A1 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023189A2 (en) 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US7362274B1 (en) 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
ES2329930T3 (es) 2005-02-11 2009-12-02 Nolabs Ab Dispositivo, metodo y uso para el tratamiento de la neuropatia con oxido nitrico.
WO2006128032A2 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
MY166532A (en) * 2006-02-10 2018-07-10 Mannatech Inc All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US8333997B2 (en) 2006-06-21 2012-12-18 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
AU2008219834C1 (en) 2007-02-26 2015-11-12 Heartbeet Ltd. New use of nitrites and nitrates and compositions containing these
US9180140B2 (en) 2007-02-26 2015-11-10 Heartbeet Ltd. Performance enhancing composition and use thereof
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
JP5592790B2 (ja) * 2007-08-06 2014-09-17 トリニティ ラボラトリーズ インコーポレイテッド 慢性疼痛およびニューロパシーに関連する疼痛を治療する医薬組成物
US9649334B2 (en) 2007-11-15 2017-05-16 The Uab Research Foundation Use of nitrite salts in chronic ischemia
AU2008345034A1 (en) 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) * 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
US20120237617A1 (en) 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
CA2777066C (en) * 2009-10-14 2020-02-18 TheraVasc, LLC Pharmaceutical formulations of nitrite and uses thereof
US20140127329A1 (en) 2011-03-31 2014-05-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
WO2012142413A2 (en) 2011-04-14 2012-10-18 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications

Similar Documents

Publication Publication Date Title
JP2013508289A5 (enExample)
HRP20250480T1 (hr) Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
RU2012147739A (ru) Пероральные составы, содержащие аналоги цитидина, и способы их использования
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2012502047A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2012180381A5 (enExample)
JP2012193216A5 (enExample)
JP2015038135A5 (enExample)
MX2011007779A (es) Formulaciones galenicas de compuestos organicos.
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2014503593A5 (enExample)
EP2493312A4 (en) Solid pharmaceutical compositions containing an integrase inhibitor
JP2009513713A5 (enExample)
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
NZ611026A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
WO2007145863A3 (en) Sustained release formulation of naltrexone
JP2016512247A5 (enExample)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2016505050A5 (enExample)
JP2008088189A5 (enExample)
JP2013544795A5 (enExample)